CELGENE CORP /DE/ | 2013 | FY | 3


Other Financial Information
Accrued expenses at December 31, 2013 and 2012 consisted of the following:
 
 
2013
 
2012
Compensation
 
$
261.7

 
$
170.3

Rebates, distributor chargebacks and distributor services
 
217.3

 
187.0

Clinical trial costs and grants
 
192.6

 
183.3

Common share repurchases
 
45.7

 
41.0

Interest
 
49.0

 
26.3

Royalties, license fees and collaboration agreements
 
52.4

 
19.4

Commercial related activities
 
46.6

 
22.8

Sales returns
 
15.5

 
13.3

Rent
 
14.8

 
9.5

Professional services
 
9.3

 
9.8

Other Taxes
 
7.6

 
8.3

Other
 
88.6

 
84.7

Total
 
$
1,001.1

 
$
775.7



Other current liabilities at December 31, 2013 and 2012 consisted of the following:
 
 
2013
 
2012
Contingent value rights – Abraxis acquisition
 
$

 
$
277.4

Sales, use and value added tax
 
50.9

 
56.9

Foreign exchange contracts
 
55.9

 
33.3

Collaboration agreement
 
7.0

 
17.0

Contingent consideration – Avila acquisition
 
62.7

 
17.4

Other
 
23.2

 
29.3

Total
 
$
199.7

 
$
431.3


Other non-current liabilities at December 31, 2013 and 2012 consisted of the following:
 
 
2013
 
2012
Contingent consideration – Avila acquisition
 
$
147.5

 
$
163.5

Deferred compensation and long-term incentives
 
127.2

 
99.2

Contingent value rights - Abraxis acquisition
 
118.1

 

Foreign exchange contracts
 
89.6

 
0.6

Deferred lease incentive
 
28.7

 
31.4

Collaboration agreement
 
28.0

 

Contingent consideration – Gloucester acquisition
 
18.3

 
17.3

Manufacturing facility purchase
 
13.9

 
14.4

Other
 
11.4

 
29.1

Total
 
$
582.7

 
$
355.5


us-gaap:SupplementalBalanceSheetDisclosuresTextBlock